Neurogene (NGNE) Gains from Investment Securities (2013 - 2026)
Neurogene (NGNE) reported Gains from Investment Securities of $6000.0 for Q1 2026, down 60.0% on a YoY basis from $15000.0 in Q1 2025, and up 120.69% quarter-over-quarter from -$29000.0 in Q3 2025.
Neurogene (NGNE) Gains from Investment Securities (2013 - 2026) Analysis & Trends
Neurogene has reported Gains from Investment Securities for 14 years, with the latest figure at $6000.0 in Q1 2026.
- For the quarter ending Q1 2026, Gains from Investment Securities fell 60.0% year-over-year to $6000.0; the trailing twelve-month figure through Mar 2026 stood at -$9000.0 (down 114.06% YoY), and the FY2024 full-year result was $60000.0, changed N/A from the prior year.
- Gains from Investment Securities for Q1 2026 stood at $6000.0, up from -$29000.0 in the prior quarter.
- The five-year high for Gains from Investment Securities was $200000.0 in Q2 2023, with the low at -$53000.0 in Q4 2022.
- Historically, Gains from Investment Securities has averaged $17000.0 across 5 years, with a median of $11000.0 in 2024.
- The largest YoY upside for Gains from Investment Securities was 20100.0% in 2023 against a maximum downside of 185.19% in 2023.
- Neurogene's Gains from Investment Securities stood at -$53000.0 in 2022, then gained by 13.21% to -$46000.0 in 2023, then surged by 176.09% to $35000.0 in 2024, then tumbled by 182.86% to -$29000.0 in 2025, then jumped by 120.69% to $6000.0 in 2026.
- The last three Gains from Investment Securities figures came in at $6000.0 (Q1 2026), -$29000.0 (Q3 2025), and $14000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Neurogene | 216.17 Mn | 216.17 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6,000.00 |
| Mar 31, 2026 | 6,000.00 |
| Sep 30, 2025 | -29,000.00 |
| Sep 30, 2025 | -29,000.00 |
| Jun 30, 2025 | 14,000.00 |
| Jun 30, 2025 | 14,000.00 |
| Mar 31, 2025 | 15,000.00 |
| Mar 31, 2025 | 15,000.00 |
| Dec 31, 2024 | 35,000.00 |
| Dec 31, 2024 | 35,000.00 |
| Jun 30, 2024 | 14,000.00 |
| Jun 30, 2024 | 14,000.00 |
| Mar 31, 2024 | 11,000.00 |
| Mar 31, 2024 | 11,000.00 |
| Sep 30, 2023 | -46,000.00 |
| Sep 30, 2023 | -46,000.00 |
| Jun 30, 2023 | 200,000.00 |
| Jun 30, 2023 | 200,000.00 |
| Dec 31, 2022 | -53,000.00 |
| Dec 31, 2022 | -53,000.00 |